Damian J Green

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
  2. pmc Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
  3. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
  4. pmc Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Blood 116:4231-9. 2010
  5. pmc Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 121:3759-67. 2013
  6. pmc Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Clin Cancer Res 17:7373-82. 2011
  7. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009
  8. pmc Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 19:1403-6. 2013
  9. pmc Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
    Lihua E Budde
    825 Eastlake Ave E, G3 200, Seattle, WA, USA
    J Clin Oncol 29:3023-9. 2011
  10. pmc Pulmonary embolization of fat and bone marrow in cynomolgus Macaques (Macaca fascicularis)
    Derek L Fong
    Washington National Primate Research Center, University of Washington, USA
    Comp Med 61:86-91. 2011

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
    ..We are optimistic that this novel approach will provide a meaningful prolongation of survival for patients with relapsed or refractory lymphomas...
  2. pmc Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
    ..These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma...
  3. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
    ..These data suggest that anti-CD45 PRIT using an α-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia...
  4. pmc Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Blood 116:4231-9. 2010
    ..0001). Treatment was well tolerated, with no treatment-related mortalities. This study demonstrates the favorable biodistribution profile and excellent therapeutic efficacy attainable with ²¹³Bi-labeled anti-CD20 PRIT...
  5. pmc Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 121:3759-67. 2013
    ..7 K/µL 2 weeks after HSCT and recovery by 4 weeks. These data suggest that (211)At-anti-CD45 RIT in conjunction with HSCT may be a promising therapeutic option for AML...
  6. pmc Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Clin Cancer Res 17:7373-82. 2011
    ..We engineered a series of SAv FPs that downmodulate the affinity of SAv for biotin, while retaining high avidity for divalent DOTA-bis-biotin to circumvent this problem...
  7. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009
    ..We hypothesize that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of survival for patients with relapsed lymphomas compared with currently available treatment strategies...
  8. pmc Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 19:1403-6. 2013
    ..These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT...
  9. pmc Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
    Lihua E Budde
    825 Eastlake Ave E, G3 200, Seattle, WA, USA
    J Clin Oncol 29:3023-9. 2011
    ....
  10. pmc Pulmonary embolization of fat and bone marrow in cynomolgus Macaques (Macaca fascicularis)
    Derek L Fong
    Washington National Primate Research Center, University of Washington, USA
    Comp Med 61:86-91. 2011
    ..FE and FES represent important research confounders and FES should be considered as a differential diagnosis for clinical complications subsequent to skeletal trauma...
  11. doi request reprint Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies
    Eneida R Nemecek
    Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
    Cancer Biother Radiopharm 23:181-91. 2008
    ..We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model...